Mark A. Tepper, Ph.D.
President and CEO
Dr. Tepper has more than twenty years of leadership
experience in pharmaceutical and biotech companies including Bristol Myers Squibb, Serono, CytRx, RXi Pharmaceuticals and NKT Therapeutics. He has been involved in the discovery, development, and approval of a number of marketed drugs including Deoxyspergualin, Taxol, Rebif, Orcenia and Gonal-F. He has successfully founded and led
a number of therapeutics based biotech companies and raised over
$45M in funding for these companies and provided investors with a high ROI. Dr. Tepper received a Ph.D. in Biochemistry & Biophysics from Columbia University, New York, and a B.A in Chemistry (Cum Laude) from Clark University, Worcester, Mass. He gained postdoctoral training at the University of Massachusetts Medical School, Worcester, MA in the
laboratory of Professor Michael P. Czech.

Ramon Mohanlal, M.D., Ph.D., MBA
Chief Medical Officer
Dr. Mohanlal has over 15 years of research and management experience inthe pharmaceutical and biotech industry and has held positions with increasing seniority at GlaxoWelcome (GSK), Pharmacia (Pfizer), Vertex Pharmaceuticals and Interleukin Genetics, where he held the position as Chief Medical Officer. In addition, he was CEO of Syntium, a company focused on licensing and due diligence. He has developed many small molecules and biologic drugs throughout his career with a focus on advancing preclinical stage programs into clinical phase I and clinical POC (phase IIa). In addition he obtained significant late stage (Phase IIb and III) clinical and regulatory filing experience. He has extensive
drug development experience in inflammation, immunology, CNS, CV, dermatology, oncology, anti-Infectives and antivirals with several compounds reaching the market place. He obtained his MD and PhD at the University of Leiden, The Netherlands, with postgraduate clinical training at the Chelsea & Westminster Hospital, London, UK, and his MBA at the American Intercontinental University, Illinois, USA, with postgraduate business training at the MIT/Sloan School of Management, Cambridge, USA.

Founders
Advisors

Sumner Burstein, Ph.D.
Prof. Burstein has been a faculty member of the
Department of Biochemistry & Molecular Pharmacology
at The University of Massachusetts Medical School since
1977. His research activities have centered on the
structure and function of natural and synthetic
cannabinoids for which he has received continuous NIH
support since 1967. An important discovery from his research on
cannabinoids was the elucidation of the principal route of metabolism of
THC, the psychoactive agent present in the Cannabis plant. He
demonstrated that terminal carboxylic acid metabolites, which are non-
psychoactive, have potential as analgesic and anti-inflammatory
agents. This resulted in the design and proof-of-principal of ajulemic
acid (JBT-101) as a viable drug candidate for pain and inflammation.
Prior to 1977 Dr. Burstein was a Senior Scientist at The Worcester
Foundation for Experimental Biology where, in addition to his studies on
cannabinoids, he worked in the areas of steroids and prostaglandins
biochemistry. Before joining the Worcester Foundation, he was a
Postdoctoral Fellow in the chemistry department at The Weitzman
Institute in Israel. He received his doctoral degree at Wayne State
University, a master’s degree at Brandeis University and a bachelor’s
degree at MIT, all in the field of chemistry.

Robert Zurier, M.D.
Robert B Zurier MD has been Professor of Medicine at
the University of Massachusetts Medical School in
Worcester since 1991, and was Chief of Rheumatology
there until 2007. From 1980-1991 he was Professor of
Medicine and Chief of Rheumatology at the University
of Pennsylvania School of Medicine in Philadelphia. Dr.
Zurier graduated from the University of Texas
Southwestern Medical School in Dallas, trained in
Internal Medicine at Boston City Hospital, then practiced generalinternal
medicine for three years before training in clinical and research
rheumatology at NYU-Bellevue Medical Center in New York City. Dr.
Zurier’s clinical, research, and teaching accomplishments have been
recognized by election to the American Society of Clinical Investigation,
the Interurban Clinical Club, (President, 1987), Who’s Who In America,
Best Doctors in America, designation as Master of the American College
of Rheumatology, and presentation of the Physician’s Recognition
Award by the Arthritis Foundation, Massachusetts Chapter.

Mark A. Tepper, Ph.D.

Kollol Pal, Ph.D., MBA

Paul Goldenheim, M.D. – Clinical and scientific expert in pain. Dr.
Goldenheim is an industry veteran with scientific and medical expertise
in pain as well as business expertise in startup and specialty
pharmaceuticals. Previous positions include Executive Vice President,
Worldwide Research and Development, and Chief Scientific Officer of
Purdue Pharma as well as President of Transform Pharmaceuticals,
which was acquired by Johnson & Johnson in 2006 for $230 million.

Nat Katz, M.D. – Clinical and regulatory expert in pain and analgesia.
Dr. Katz is CEO of Analgesic Research. Dr. Katz is an internationally
known expert in pain management and analgesic clinical trials. His
contributions to research include numerous clinical trials of treatments
for pain, involving pharmaceuticals, non-pharmaceutical analgesics and
devices, with a particular focus on opioids and risk management. From
2000-2004 Dr. Katz served as Chair of the FDA Advisory Committee,
Anesthesia, Critical Care, and Addiction Products Division.

George Kunos, M.D., Ph.D. – Scientific expert in pain and analgesia.
Dr. Kunos is Scientific Director of National Institute of NIAAA.
Previously he has held academic positions at McGill University and the
Medical College of Virginia. Dr. Kunos' laboratory is studying the role
of endocannabinoids in neuroendocrine, metabolic and cardiovascular
regulation. He is recipient of the Mechoulam Award of the Intl.
Cannabinoid Research Society and the NIH Director's Award.

Lynn Van Campen, Ph.D. – Scientific expert in formulation. Dr. Van
Campen is the former Vice President of Pharmaceutics Development at
Inhale Therapeutics Systems and the former Director of Pharmaceutics
at Boehringer Ingelheim Pharmaceuticals. She is an expert in the
formulation development of both large and small molecules and
various modes of delivery including oral, topical, and aerosol. She was
the founding Director of the Zeeh Pharmaceutical Experimental Station
at the University of Wisconsin.